{
  "id": 8017347,
  "title": "Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026",
  "url": "https://urgent.news/2026/09/17/fennec-pharmaceuticals-announces-oral-presentation-of-detailed",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T11:36:51.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/fennec-pharmaceuticals-announces-oral-presentation-of-detailed-results-from-investigator-initiated-phase-2-sts-j01-clinical-study-of-pedmark-in-japan-at-siop-2026"
  },
  "original_language": "en",
  "account": "Fennec Pharmaceuticals plans to present detailed results from their Phase 2 STS-J01 clinical study of Pedmark® in Japan at the International Society of Pediatric Oncology (SIOP) meeting in 2026. This open-label, single-arm trial aimed to assess the effectiveness of Pedmark® in preventing cisplatin-induced ototoxicity in pediatric patients with various solid tumors.",
  "summary": "~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~ ~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~ ~ Objective Responses Observed in 23 of 24 […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}